Phase 2, 1 prior line of therapy, No Maintenance, Carfilzomib Maintenance, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM)
### Instruction:
Identify the study with the following condition. 
### Input:
Phase 2, 1 prior line of therapy, No Maintenance, Carfilzomib Maintenance, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM) 
### Output:
Popular Name is MUK Five, Study ID is ISRCTN17354232